Preclinical Efficacy Of The Trastuzumab Duocarmazine SYD985 As Monotherapy Or In Combination With The PARP Inhibitor Niraparib In HER2-Expressing Endometrial Cancer

Jivadco (trastuzumab duocarmazine) - Byondis, Medac

Zejula (niraparib) - GSK, J&J

https://eposters.emma.events/esgo2024eposters/

Cristian Pablo Moiola; Carlos Lopez-Gil; Marta Rebull; Melek Denizli; Ana Sotoca-Covaleda; Vicente Bebia; Lourdes Salazar; Silvia Cabrera; Monique Van Der Vleuten; Patrick Groothuis; Antonio Gil-Moreno; Eva Colas

Jan 18, 2024